SDK Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• IV Arsenic Trioxide · Oncology
  Arsenic trioxide induces differentiation and apoptosis of leukemic cells, particularly in acute promyelocytic leukemia, through multiple pathways including PML-RARA degradation and reactive oxygen species generation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• SDK Therapeutics, Inc. portfolio CI brief
• SDK Therapeutics, Inc. pipeline updates RSS